Professor Sir Chris Evans’ Lab21 achieves first product registration in China

Cambridge, UK – 1st June 2010 - Lab21 Limited, the healthcare diagnostics company, is pleased to announce that it has achieved its first product registration in the People’s Republic of China, thereby further extending the number of territories in which its market leading range of diagnostic and blood-banking products are available.
The first Lab21 product registered in China is a TPHA assay used in syphilis screening.
Graham Mullis, Lab21’s CEO, stated: “Lab21 will now supply its TPHA product via its distribution partner into China, one of the currently fastest growing in-vitro diagnostic markets. The Chinese IVD market has a value in the region of US$1.5bn and is the world’s seventh largest, expanding at 15% annually. Our TPHA assay is already the leading syphilis assay in a number of key blood screening markets and we are delighted to make it available in another key region.”
Hayden Jeffreys, Divisional Director for Diagnostic Products at Lab21, added: “We are delighted to be able to expand our product coverage into this geographical region and we anticipate that this will be the first of a number of our products to be registered in the Chinese market, planned over the next 18 months.”